{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:00:32Z","timestamp":1790636432922,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01516-9","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:28:04Z","timestamp":1781278084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors"],"prefix":"10.1038","volume":"10","author":[{"given":"Harold Nathan","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaoula Ben Haj","family":"Frej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Fossella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecaterina E.","family":"Dumbrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","volume":"17","author":"A Marx","year":"2022","unstructured":"Marx, A. et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors. J. Thorac. Oncol. 17, 200\u2013213 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1516_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jtho.2018.01.013","volume":"13","author":"N Girard","year":"2018","unstructured":"Girard, N. Thymic tumors: revisiting autoimmunity to give a chance to immunotherapy. J. Thorac. Oncol. 13, 295\u2013297 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.jtho.2025.04.013","volume":"20","author":"S Fodil-Cherif","year":"2025","unstructured":"Fodil-Cherif, S. et al. Characterization, prognosis, and treatment of patients with locally advanced or metastatic thymic neuroendocrine tumor: a retrospective study of the French GTE, ENDOCAN RENATEN, and RYTHMIC networks. J. Thorac. Oncol. 20, 1315\u20131327 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","volume":"6","author":"FC Detterbeck","year":"2011","unstructured":"Detterbeck, F. C., Nicholson, A. G., Kondo, K., Van Schil, P. & Moran, C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J. Thorac. Oncol. 6, S1710\u2013S1716 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.jtho.2023.09.002","volume":"18","author":"E Ruffini","year":"2023","unstructured":"Ruffini, E. et al. The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: proposal for a stage classification for the forthcoming ninth edition of the TNM classification of malignant tumors. J. Thorac. Oncol. 18, 1655\u20131671 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1516_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33170-7","volume":"13","author":"Z Xin","year":"2022","unstructured":"Xin, Z. et al. The immune landscape of human thymic epithelial tumors. Nat. Commun. 13, 5463 (2022).","journal-title":"Nat. Commun."},{"key":"1516_CR7","doi-asserted-by":"publisher","first-page":"7864","DOI":"10.3390\/ijms23147864","volume":"23","author":"C Masaoutis","year":"2022","unstructured":"Masaoutis, C., Palamaris, K., Kokkali, S., Levidou, G. & Theocharis, S. Unraveling the immune microenvironment of thymic epithelial tumors: implications for autoimmunity and treatment. Int. J. Mol. Sci. 23, 7864 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1516_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/cancers16071369","volume":"16","author":"A Rajan","year":"2024","unstructured":"Rajan, A., Sivapiromrat, A. K. & McAdams, M. J. Immunotherapy for thymomas and thymic carcinomas: current status and future directions. Cancers 16, 1369 (2024).","journal-title":"Cancers"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"917743","DOI":"10.3389\/fonc.2022.917743","volume":"12","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms. Front. Oncol. 12, 917743 (2022).","journal-title":"Front. Oncol."},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","volume":"43","author":"SL Wang","year":"2025","unstructured":"Wang, S. L. & Chan, T. A. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell 43, 641\u2013664 (2025).","journal-title":"Cancer Cell"},{"key":"1516_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jtho.2020.12.007","volume":"16","author":"A Rajan","year":"2021","unstructured":"Rajan, A. Immunotherapy for thymic cancers: a convoluted path toward a cherished goal. J. Thorac. Oncol. 16, 352\u2013354 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1516_CR12","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"J Cho","year":"2019","unstructured":"Cho, J. et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J. Clin. Oncol. 37, 2162\u20132170 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1516_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone, G. et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 19, 347\u2013355 (2018).","journal-title":"Lancet Oncol."},{"key":"1516_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101576","volume":"8","author":"N Girard","year":"2023","unstructured":"Girard, N. et al. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open 8, 101576 (2023).","journal-title":"ESMO Open"},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"1176450","DOI":"10.3389\/fimmu.2023.1176450","volume":"14","author":"M Matsumoto","year":"2023","unstructured":"Matsumoto, M., Yoshida, H., Tsuneyama, K., Oya, T. & Matsumoto, M. Revisiting Aire and tissue-restricted antigens at single-cell resolution. Front. Immunol. 14, 1176450 (2023).","journal-title":"Front. Immunol."},{"key":"1516_CR16","doi-asserted-by":"publisher","first-page":"7571","DOI":"10.21037\/jtd-2019-thym-10","volume":"12","author":"TG Blum","year":"2020","unstructured":"Blum, T. G., Misch, D., Kollmeier, J., Thiel, S. & Bauer, T. T. Autoimmune disorders and paraneoplastic syndromes in thymoma. J. Thorac. Dis. 12, 7571\u20137590 (2020).","journal-title":"J. Thorac. Dis."},{"key":"1516_CR17","doi-asserted-by":"publisher","first-page":"926625","DOI":"10.3389\/fimmu.2022.926625","volume":"13","author":"J B\u0159ezina","year":"2022","unstructured":"B\u0159ezina, J., Vobo\u0159il, M. & Filipp, D. Mechanisms of direct and indirect presentation of self-antigens in the thymus. Front. Immunol. 13, 926625 (2022).","journal-title":"Front. Immunol."},{"key":"1516_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01772-4","volume":"22","author":"YQ Ao","year":"2023","unstructured":"Ao, Y. Q. et al. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. Mol. Cancer 22, 70 (2023).","journal-title":"Mol. Cancer"},{"key":"1516_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","volume":"23","author":"F Conforti","year":"2022","unstructured":"Conforti, F. et al. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 1287\u20131296 (2022).","journal-title":"Lancet Oncol."},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","volume":"26","author":"T Shukuya","year":"2025","unstructured":"Shukuya, T. et al. Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 26, 331\u2013342 (2025).","journal-title":"Lancet Oncol."},{"key":"1516_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1516_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy, M. & Naidoo, J. Immune-related adverse events and the balancing act of immunotherapy. Nat. Commun. 13, 392 (2022).","journal-title":"Nat. Commun."},{"key":"1516_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1158\/0008-5472.CAN-17-2802","volume":"78","author":"MA Gadhikar","year":"2018","unstructured":"Gadhikar, M. A. et al. CDKN2A\/p16 deletion in head and neck cancer cells is associated with CDK2 activation, replication stress, and vulnerability to CHK1 inhibition. Cancer Res 78, 781\u2013797 (2018).","journal-title":"Cancer Res"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2022.07.016","volume":"143","author":"IZM Kreuger","year":"2023","unstructured":"Kreuger, I. Z. M., Slieker, R. C., van Groningen, T. & van Doorn, R. Therapeutic strategies for targeting CDKN2A loss in melanoma. J. Invest. Dermatol. 143, 18\u201325.e1 (2023).","journal-title":"J. Invest. Dermatol."},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ymthe.2022.01.044","volume":"30","author":"ZJ Long","year":"2022","unstructured":"Long, Z. J., Wang, J. D., Xu, J. Q., Lei, X. X. & Liu, Q. cGAS\/STING cross-talks with cell cycle and potentiates cancer immunotherapy. Mol. Ther. 30, 1006\u20131017 (2022).","journal-title":"Mol. Ther."},{"key":"1516_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","volume":"18","author":"HA Jung","year":"2023","unstructured":"Jung, H. A. et al. A phase 2 study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21). J. Thorac. Oncol. 18, 223\u2013231 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1516_CR27","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","volume":"27","author":"E Adib","year":"2021","unstructured":"Adib, E. et al. CDKN2A alterations and response to immunotherapy in solid tumors. Clin. Cancer Res. 27, 4025\u20134035 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1516_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/0008-5472.CAN-24-1817","volume":"85","author":"S Wang","year":"2025","unstructured":"Wang, S. et al. Loss of CDKN2A enhances the efficacy of immunotherapy in EGFR-mutant non-small cell lung cancer. Cancer Res. 85, 585\u2013601 (2025).","journal-title":"Cancer Res."},{"key":"1516_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"NK Altorki","year":"2019","unstructured":"Altorki, N. K. et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer 19, 9\u201331 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"1516_CR30","doi-asserted-by":"publisher","first-page":"1148389","DOI":"10.3389\/fmolb.2023.1148389","volume":"10","author":"L Carlsen","year":"2023","unstructured":"Carlsen, L. et al. The role of p53 in anti-tumor immunity and response to immunotherapy. Front. Mol. Biosci. 10, 1148389 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"1516_CR31","doi-asserted-by":"publisher","first-page":"667148","DOI":"10.3389\/fonc.2021.667148","volume":"11","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Frequent genetic alterations and their clinical significance in patients with thymic epithelial tumors. Front. Oncol. 11, 667148 (2021).","journal-title":"Front. Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01516-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:35:39Z","timestamp":1790634939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01516-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01516-9","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.N.T., H.L., K.B.H.F., L.K., and F.F. have no relationships to disclose. E.S. has a consulting\/advisory role for D.E. Shaw Research; owns a patent for atezolizumab for treatment of alveolar soft part sarcoma; and participated on a data safety monitoring board or advisory board for FortVita and Mallinckrodt\/Therakos. S.C. Speakers\u2019 Bureau \u2013 Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Genmab, Janssen, Merck KGaA, Merck, Novartis, Roche, Servier; Research Funding \u2013 Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bolt Biotherapeutics, Centessa Pharmaceuticals, Cytovation, Eisai, Exelixis, GlaxoSmithKline, Imcheck Therapeutics, Immunocore, Kumquat Biosciences, Marengo, Molecular Partners AG, Merck, OncoC4, Ose Immunotherapeutics, Owkin, Pheast, Pierre Fabre, Replimune, Roche, Sanofi Aventis, Seagen, Sotio A.S, Transgene, Trutino Biosciences, Consulting\/Advisory Role \u2013 AccessTrial, Alderaan Biotechnology, Amgen; AstraZeneca, Aummune, Avacta, Bayer, Beigene, BioNTech, Celanese, Compugen, Domain Therapeutics, Ellipses Pharma, GE Health, Genmab, Guardant Health, Immunicom, Mariana Oncology, Mima Health, Nanobiotix, Nextcure, NetCancer, Oncovita, Pharma Mar, Pierre Fabre, Replimune, Seagen, Takeda, Tatum Bioscience, Tollys, UltraHuman8; Travel\/Accommodations\/Expenses \u2013 Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck, Ose Immunotherapeutics, Roche, Sotio; Stocks \u2013 Avacta. F.M.-B. Employment \u2013 MD Anderson Cancer Center; Honoraria \u2013 Dava Oncology; Consulting\/Advisory Role \u2013 AstraZeneca, Becton Dickinson, Calibr, Cybrexa Therapeutics, Daiichi Sankyo\/AstraZeneca, DAVA Pharmaceuticals, Debiopharm Group, EcoR1 Capital, eFFECTOR Therapeutics, Elevation Oncology, Exelixis, GT Aperion, Guardant Health, Harbinger Health, Incyte, Jazz Pharmaceuticals, LegoChem Biosciences, Loxo\/Lilly, Menarini Group, Mersana, Molecular Templates, OnCusp Therapeutics, Protai, Ribometrix, Seagen, Tempus, Theratechnologies, Zentalis, Zymeworks; Research Funding \u2013 Aileron Therapeutics (Inst), AstraZeneca (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Calithera Biosciences (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Debiopharm Group (Inst), eFFECTOR Therapeutics (Inst), Genentech (Inst), Guardant Health (Inst), Jazz Pharmaceuticals (Inst), Klus Pharma (Inst), Novartis (Inst), Pfizer (Inst), PUMA Biotechnology (Inst), Seagen (Inst), Taiho Pharmaceutical (Inst), Takeda Pharmaceutical (Inst), Zymeworks (Inst); Travel\/Accommodations\/Expenses \u2013 Cholangiocarcinoma Foundation, Dava Oncology, ESMO, EORTC. A.N. Employment \u2013 Baylor College of Medicine and Texas Children\u2019s Hospital (I), MD Anderson Cancer Center; Honoraria \u2013 AKH Inc., American Society of Clinical Oncology, CME Outfitters, ESMO, Korean Society of Medical Oncology (KSMO), Lynx Group, Scripps Hospital, Society for Immunotherapy of Cancer; Consulting\/Advisory Role \u2013 Abbvie, CytomX Therapeutics, Deka Biosciences, Genome & Company, Horizon Therapeutics (I), Immune-Onc Therapeutics, Janssen Biotech, Lynx Health, Merck Sharp & Dohme Corp, NGM Biopharmaceuticals, Nouscom, OncoSec, Pharming NV (I), PsiOxus Therapeutics, Servier, STCube Pharmaceuticals Inc., Takeda (I); Speakers\u2019 Bureau \u2013 Alfaisal University (I); Research Funding \u2013 Amplimmune, Arcus Biosciences, ARMO BioSciences, Atterocor, Baxalta (I), BioNTech SE, Bristol-Myers Squibb, Calithera Biosciences, Chao Physician-Scientist Awards (I), CytomX Therapeutics, EMD Serono, Healios, Immune Deficiency Foundation (I), ImmuneOncia, Incyte, Jeffrey Modell Foundation (I), Karyopharm Therapeutics, Kymab, Lilly, MedImmune, Merck, Monopteros Therapeutics, NCI, NeoImmuneTech, Neon Therapeutics, Novartis, Pfizer, PsiOxus Therapeutics, Regeneron, Seven and Eight Biopharmaceuticals, Sotio, Surface Oncology, Texas Medical Center Digestive Diseases Center (I), TopAlliance BioSciences Inc; Travel\/Accommodations\/Expenses \u2013 ARMO BioSciences, NeoImmuneTech, NGM Biopharmaceuticals. M.A. Research Funding \u2013 Genentech (Inst), Nektar Therapeutics (Inst), Merck (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Jounce Therapeutics (Inst), Bristol Myers Squibb (Inst), Eli Lilly (Inst), Adaptimmune (Inst), Shattuck Lab (Inst), Gilead (Inst), BioNTech (Inst), Henlius (Inst), Vivace Therapeutics (Inst), Verismo Therapeutics (Inst), Pfizer (Inst); Consulting\/Advisory Role \u2013 GlaxoSmithKline, Shattuck Lab, Bristol Myers Squibb, AstraZeneca, Insight; Honoraria \u2013 AstraZeneca, Nektar Therapeutics, Society for Immunotherapy of Cancer (SITC); Participation on a Data Safety Monitoring Board or Advisory Board \u2013 Nanobiotix\u2013MDA Alliance, Henlius. E.E.D. Consulting\/Advisory Role \u2013 BOLT Biotherapeutics, Fate Therapeutics, Mersana, PMV Pharma, Summit Therapeutics; Speakers\u2019 Bureau \u2013 PMV Pharma; Research Funding \u2013 A2A Pharmaceuticals (Inst), Aileron Therapeutics (Inst), Amgen (Inst), Aprea Therapeutics (Inst), Astex Pharmaceuticals (Inst), AstraZeneca (Inst), Bayer (Inst), Bellicum Pharmaceuticals (Inst), Boehringer Ingelheim (Inst), BOLT Biotherapeutics (Inst), Compugen (Inst), Dragonfly Therapeutics (Inst), Fate Therapeutics (Inst), Genentech (Inst), Immunocore (Inst), Immunomedics\/Gilead (Inst), Mereo BioPharma 5 (Inst), Mersana (Inst), ModeX Therapeutics (Inst), Pfizer (Inst), PMV Pharma (Inst), Poseida (Inst), Rain Therapeutics (Inst), Sanofi (Inst), Sotio (Inst), Triumvira Immunologics (Inst), Volastra Therapeutics (Inst); Travel\/Accommodations\/Expenses \u2013 Boehringer Ingelheim, Rain Oncology, Triumvira Immunologics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"363"}}